AngioDynamics Awarded Premier Inc.'s Supplier Horizon Award

        Print
| Source: AngioDynamics

ALBANY, N.Y., June 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it is a winner of Premier Inc.'s first Supplier Horizon Award, presented at Premier's annual Breakthroughs Conference and Exhibition at the Henry B. Gonzalez Convention Center in San Antonio.

Premier is a leading healthcare improvement company that contracts with more than 1,100 suppliers on behalf of approximately 3,000 U.S. hospitals and over 100,000 other medical providers. Only eight companies were recognized this year by Premier in areas such as Facilities; Foodservice; Materials Management; Nursing; Pediatrics; Pharmacy; Purchased Services and Surgical Services. AngioDynamics was recognized in the Nursing category, and winners were selected for their support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.

"We are thrilled to be named among Premier's inaugural Supplier Horizon Award winners," said Chuck Greiner, Senior Vice President of AngioDynamics' Global Vascular Access Franchise. "Not only is it a testament to the continued acceptance and utilization of our innovative, thromboresistant BioFlo PICCs, it specifically illustrates our deep-rooted commitment to supporting the supply chain and Premier's members by presenting them with clinical and economic value."

"AngioDynamics supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies," said Durral R. Gilbert, president of supply chain services, Premier. "We're honored to recognize them as one of the first Horizon Award recipients."

About Premier Inc.

Premier Inc. is a leading healthcare improvement company, uniting the alliance of approximately 3,000 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Company Contact:
AngioDynamics Inc.
Mark Frost, CFO
(800) 772-6446 x1981


Investor Relations Contacts:
EVC Group, Inc.
Michael Polyviou/Robert Jones
(212) 850-6020; (646) 201-5447
; 

Media Contact:
EVC Group, Inc.
Dave Schemelia
(646) 201-5431